EAM Investors LLC Has $4.63 Million Stake in Akebia Therapeutics, Inc. (AKBA)

EAM Investors LLC lifted its holdings in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) by 5.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 235,470 shares of the biopharmaceutical company’s stock after buying an additional 12,330 shares during the quarter. EAM Investors LLC owned about 0.50% of Akebia Therapeutics worth $4,632,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of AKBA. SG Americas Securities LLC acquired a new stake in shares of Akebia Therapeutics during the 2nd quarter worth approximately $132,000. Legal & General Group Plc grew its holdings in Akebia Therapeutics by 8.0% during the second quarter. Legal & General Group Plc now owns 9,672 shares of the biopharmaceutical company’s stock valued at $142,000 after purchasing an additional 714 shares during the period. Creative Planning grew its holdings in Akebia Therapeutics by 2.9% during the second quarter. Creative Planning now owns 10,650 shares of the biopharmaceutical company’s stock valued at $153,000 after purchasing an additional 300 shares during the period. Cubist Systematic Strategies LLC acquired a new position in Akebia Therapeutics during the second quarter valued at approximately $159,000. Finally, Macquarie Group Ltd. acquired a new position in Akebia Therapeutics during the third quarter valued at approximately $183,000. Institutional investors own 60.09% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://sportsperspectives.com/2017/11/20/eam-investors-llc-has-4-63-million-stake-in-akebia-therapeutics-inc-akba.html.

A number of research analysts recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $24.00 price objective on shares of Akebia Therapeutics in a report on Wednesday, November 15th. Zacks Investment Research upgraded shares of Akebia Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 price objective for the company in a report on Monday, November 13th. Mizuho restated a “buy” rating and set a $24.00 price objective on shares of Akebia Therapeutics in a report on Thursday, November 9th. Royal Bank Of Canada restated a “hold” rating and set a $17.00 price objective on shares of Akebia Therapeutics in a report on Thursday, November 2nd. Finally, ValuEngine upgraded shares of Akebia Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Akebia Therapeutics presently has an average rating of “Buy” and a consensus target price of $20.75.

Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) traded up $0.23 on Monday, reaching $15.36. 315,500 shares of the company’s stock were exchanged, compared to its average volume of 514,004. Akebia Therapeutics, Inc. has a 1 year low of $7.78 and a 1 year high of $20.25.

Akebia Therapeutics (NASDAQ:AKBA) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.07. Akebia Therapeutics had a negative net margin of 137.80% and a negative return on equity of 198.85%. The firm had revenue of $41.28 million for the quarter, compared to analyst estimates of $34.00 million. equities research analysts expect that Akebia Therapeutics, Inc. will post -2.25 EPS for the current year.

In other news, SVP Michel Dahan sold 1,398 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $19.64, for a total value of $27,456.72. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In the last three months, insiders sold 7,586 shares of company stock worth $147,289. 8.67% of the stock is currently owned by insiders.

Akebia Therapeutics Profile

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Want to see what other hedge funds are holding AKBA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Akebia Therapeutics, Inc. (NASDAQ:AKBA).

Institutional Ownership by Quarter for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply